

Russia Diabetes Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

The Russia Diabetes Drugs Market size is estimated at USD 1.04 billion in 2024, and is expected to reach USD 1.31 billion by 2029, growing at a CAGR of 4.5% during the forecast period (2024-2029).

Within the first year since its inception, the COVID-19 pandemic has been responsible for premature deaths, particularly among older individuals. Russia has the ninth-highest number of confirmed cases in the world affected by COVID-19. Most people who have died of COVID-19 were affected by the co-occurrence of two or more chronic conditions in the same individual. Several studies have confirmed that chronic diseases like diabetes are associated with adverse outcomes in COVID-19 patients.

Diabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic care products. According to Roscongress, Russia ranks fifth in the world in terms of the number of patients with diabetes mellitus in the age range of 20 to 79. In addition, during COVID-19, the mortality rate among patients with diabetes increased by 22%.

In May 2021, the World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to insulin; promoting convergence and harmonization of regulatory requirements for insulin and other medicines and health products for the treatment of diabetes; and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to the transparency of markets for diabetes medicines and health products.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Russia Diabetes Drugs Market Trends

The oral anti-diabetic drugs segment holds the highest market share in the Russia Diabetes Drugs Market in the current year

The oral anti-diabetic drugs segment holds the highest market share of about 50.5% in the Russia Diabetes Drugs Market in the current year.

Oral Anti-Diabetic Drugs are available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required along with lifestyle management. Oral agents are typically the first medications used in treating type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action. Anti-diabetic drugs help diabetes patients control their condition and lower the risk of diabetes complications. People with diabetes may need to take anti-diabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. Oral anti-diabetic agents present the advantages of easier management and lower cost. So they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.

Russia witnessed an alarming increase in the prevalence of diabetes in recent years. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as oral anti-diabetic medication or ingestion of additional carbohydrates by monitoring their blood glucose levels. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity.

According to IDF, to reduce the diabetes epidemic in the country, the Russian government needs to fully implement a National Diabetes Plan that establishes a state budget and guarantees diabetes care to all Russian citizens. Russia is working towards improving the reimbursement system for all aspects of diabetes care, limiting out-of-pocket payments, and preventing households from incurring catastrophic expenditures. Also, implementing a national screening program to improve the early identification of disturbed carbohydrate metabolism and creating a specialized diabetes health service under the Ministry of Health of the Russian Federation.

Owing to the above factors, the market will likely continue to grow.

Sodium-glucose cotransport -2 (SGLT-2) inhibitor segment is expected to register the highest CAGR in the Russia Diabetes Drugs Market

Sodium-glucose cotransport -2 (SGLT-2) inhibitor segment is expected to register a CAGR of about 11.7% over the forecast period.

SGLT-2 inhibitors, also called gliflozins, are a medicine class used to lower high blood glucose levels in people with type 2 diabetes. SGLT-2 inhibitors act independently of beta-cell function in the pancreas. SGLT-2 drugs significantly manage cardiovascular risk factors, including blood pressure, cardiac function, and antiinflammatory activity. SGLT-2 inhibitors are effective at lowering hemoglobin A1c levels and improving weight loss. They include a low risk of hypoglycemia and are usually well tolerated. Technological advancements increased over the period leading to several modifications in the SGLT-2 inhibitors or the formulations being developed.

According to Roscongress, Russia ranks fifth in the world regarding the number of patients with diabetes mellitus aged 20 to 79. The growing diabetic population acts as a driver for diabetes care devices. In obese individuals, the fat cells in the body release pro-inflammatory chemicals, which may make the body less sensitive to the insulin it produces by disrupting the function of

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

insulin-responsive cells. Russia's Federal Targeted Program on Diabetes states that diagnosing diabetes and treating its complications earlier can result in significant savings.

Various initiatives are launched to control diabetes in the country. For instance, in Moscow Urban Forum 2021, a Letter of Intent was signed between the Youth Council under the Moscow Department of Health, Moscow Urban Forum, Moscow Diabetic Association, Moscow Diabetic Association Medical Section, KB Strelka, and Novo Nordisk to implement the Cities Changing Diabetes program in Moscow. The program in Moscow aims to comprehensively assess the features of diabetes challenges relevant to Moscow. The program also implemented the development of an action plan to combat this disease among the most vulnerable groups of the population.

The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among people are some of the market opportunities for the players in the Russian diabetes drugs market.

Russia Diabetes Drugs Industry Overview

The Russia Diabetes Drugs Market is moderately consolidated, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, and other generic players, holding a presence in the region. A major share of the market is held by manufacturers concomitant with strategy-based M&A operations and constantly entering the market to generate new revenue streams and boost existing ones.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Table of Contents:

1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
- 4.4 Porter's Five Forces Analysis
 - 4.4.1 Bargaining Power of Suppliers
 - 4.4.2 Bargaining Power of Consumers
 - 4.4.3 Threat of New Entrants
 - 4.4.4 Threat of Substitute Products and Services
 - 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1 Insulins
 - 5.1.1 Basal or Long Acting Insulins
 - 5.1.1.1 Lantus (Insulin Glargine)
 - 5.1.1.2 Levemir (Insulin Detemir)
 - 5.1.1.3 Toujeo (Insulin Glargine)
 - 5.1.1.4 Tresiba (Insulin Degludec)
 - 5.1.1.5 Basaglar (Insulin Glargine)
 - 5.1.2 Bolus or Fast Acting Insulins
 - 5.1.2.1 NovoRapid/Novolog (Insulin Aspart)
 - 5.1.2.2 Humalog (Insulin Lispro)
 - 5.1.2.3 Apidra (Insulin Glulisine)
 - 5.1.3 Traditional Human Insulins
 - 5.1.3.1 Novolin/Actrapid/Insulatard
 - 5.1.3.2 Humulin
 - 5.1.3.3 Insuman
 - 5.1.4 Biosimilar Insulins
 - 5.1.4.1 Insulin Glargine Biosimilars
 - 5.1.4.2 Human Insulin Biosimilars
- 5.2 Oral Anti-diabetic drugs
 - 5.2.1 Biguanides
 - 5.2.1.1 Metformin
 - 5.2.2 Alpha-Glucosidase Inhibitors
 - 5.2.2.1 Alpha-Glucosidase Inhibitors
 - 5.2.3 Dopamine D2 receptor agonist
 - 5.2.3.1 Bromocriptin
 - 5.2.4 SGLT-2 inhibitors □
 - 5.2.4.1 Invokana (Canagliflozin)
 - 5.2.4.2 Jardiance (Empagliflozin)
 - 5.2.4.3 Farxiga/Forxiga (Dapagliflozin)
 - 5.2.4.4 Suglat (Ipragliflozin)
 - 5.2.5 DPP-4 inhibitors
 - 5.2.5.1 Onglyza (Saxagliptin)
 - 5.2.5.2 Tradjenta (Linagliptin)
 - 5.2.5.3 Vipidia/Nesina(Alogliptin)
 - 5.2.5.4 Galvus (Vildagliptin)
 - 5.2.6 Sulfonylureas
 - 5.2.6.1 Sulfonylureas
 - 5.2.7 Meglitinides
 - 5.2.7.1 Meglitinides
- 5.3 Non-Insulin Injectable drugs
 - 5.3.1 GLP-1 receptor agonists□
 - 5.3.1.1 Victoza (Liraglutide)
 - 5.3.1.2 Byetta (Exenatide)
 - 5.3.1.3 Bydureon (Exenatide)
 - 5.3.1.4 Trulicity (Dulaglutide)
 - 5.3.1.5 Lyxumia (Lixisenatide)
 - 5.3.2 Amylin Analogue

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.3.2.1 Symlin (Pramlintide)
- 5.4 Combination drugs
 - 5.4.1 Insulin combinations
 - 5.4.1.1 NovoMix (Biphasic Insulin Aspart)
 - 5.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
 - 5.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
 - 5.4.2 Oral Combinations
 - 5.4.2.1 Janumet (Sitagliptin and Metformin)

6 MARKET INDICATORS

- 6.1 Type-1 Diabetic Population
- 6.2 Type-2 Diabetic Population

7 COMPETITIVE LANDSCAPE

7.1 COMPANY PROFILES

- 7.1.1 Novo Nordisk A/S
- 7.1.2 Takeda
- 7.1.3 Pfizer
- 7.1.4 Eli Lilly
- 7.1.5 Janssen Pharmaceuticals
- 7.1.6 Astellas
- 7.1.7 Boehringer Ingelheim
- 7.1.8 Merck And Co.
- 7.1.9 AstraZeneca
- 7.1.10 Bristol Myers Squibb
- 7.1.11 Novartis
- 7.1.12 Sanofi Aventis

7.2 COMPANY SHARE ANALYSIS

- 7.2.1 Novo Nordisk A/S
- 7.2.2 Sanofi Aventis
- 7.2.3 Eli Lilly
- 7.2.4 Merck And Co.
- 7.2.5 Others

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Russia Diabetes Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-28"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com